(Q33332660)

25 July 2017

1 reference

title

Gemcitabine in locally advanced and/or metastatic bladder cancer (English)

1 reference

25 July 2017

1 reference

H von der Maase

1

1 reference

25 July 2017

publication date

1 June 2000

1 reference

Critical Reviews in Oncology Hematology

25 July 2017

published in

1 reference

25 July 2017

volume

34

1 reference

25 July 2017

issue

3

1 reference

25 July 2017

page(s)

175-183

1 reference

25 July 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Bladder cancer: state-of-the-art care

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Cancer in the European community and its member states

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Chemotherapy for urothelial tract malignancies: breaking the deadlock

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2800%2900060-3

7 January 2021

10.1016/S1040-8428(00)00060-3

Identifiers

DOI

1 reference

25 July 2017

1 reference